Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2001, we proposed to restore this balance using judicious doses of antiangiogenic agents and suggested that this strategy would transiently give rise to tumour vessels with structural and functional phenotypes closer to those of the vessels of nonmalignant tissues — a state we referred to as ‘normalized’ (REF. 61)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“We also suggested that the use of other therapies during this ‘window of normalization’ (REF. 61) would result in better outcomes than if the same agents were given before or after this window.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“Traditional angiogenesis inhibitors mainly block VEGF signaling and prune rather than eradicate tumor vessels.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [78]
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“What mechanisms are responsible for this normalization? How can we exploit them? This knowledge will affect the treatment not only of cancer but also of other diseases characterized by abnormal vasculature—such as hemangiomas, arteriovenous malformations, diabetic retinopathy and macular degeneration—for which anti-an…”
BackgroundSelf-citationGenes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Self-citationLee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 733
Self-citationYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Self-citationBaish, J. W., & Jain, R. K. (2000) · PubMed · Cited by 714
Self-citationThe next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Self-citation
Research works printed but not linked: 6
- Folkman, J. in Harrison's Textbook of Internal Medicine, 15th ed. (eds Braunwald, E. et al.) 517–530 (McGraw-Hill, New York, 2001).
- Kozin, S.V. et al. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1α→HRE→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research 60, 6248–6252 (2000).
- Kadambi, A. et al. Vascular endothelial growth factor (VEGF)–C differentially affects tumor vascular function and leukocyte recruitment. Cancer Res. 61, 2404–2408 (2001).
- Lee, C.G. et al. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
- Hansen-Algenstaedt, N. et al. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556–4560 (2000).
Cited by
Items 901–1,000 of 1,004
Sonaglioni, A., Albini, A., Fossile, E., Pessi, M. A., Nicolosi, G. L., Lombardo, M., Anzà, C., & Ambrosio, G. (2020) · Cardiovascular Toxicology · doi:10.1007/s12012-020-09583-5 · Cited by 32
Metabolic pathway alterations in microvascular endothelial cells in response to hypoxia
Cohen, E. B., Geck, R. C., & Toker, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232072 · Cited by 33
Zhou, L., Yin, R., Gao, N., Sun, H., Chen, D., Cai, Y., Ren, L., Yang, L., Zuo, Z., Zhang, H., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105527 · Cited by 31
Effects of radiation on tumor vasculature
Yamazaki, T., & Young, K. H. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23360 · Cited by 32
Pharmacodynamic Aspects of Intraperitoneal Cytotoxic Therapy
Ceelen, W. P., Påhlman, L., & Mahteme, H. (2007) · Springer eBooks · doi:10.1007/978-0-387-48993-3_12 · Cited by 31
Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?
Korpanty, G. J., Smyth, E. C., & Carney, D. N. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.11.11 · Cited by 31
The promise of mTOR inhibitors in the treatment of colorectal cancer
Kim, D.-D., & Eng, C. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.721353 · Cited by 33
Kristian, A., Revheim, M. E., Qu, H., Mælandsmo, G. M., Engebråten, O., Seierstad, T., & Malinen, E. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.813634 · Cited by 31
Angiogenic and lymphangiogenic cascades in the tumor microenvironment
Onimaru, M., & Yonemitsu, Y. (2010) · Frontiers in Bioscience-Scholar · doi:10.2741/s146 · Cited by 31
Smerdel, M. P., Waldstrøm, M., Brandslund, I., Steffensen, K. D., Andersen, R. F., & Jakobsen, A. K. M. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a13168 · Cited by 31
Esposito, G., Gigli, S., Seguella, L., Nobile, N., D’Alessandro, A., Pesce, M., Capoccia, E., Steardo, L., Cirillo, C., Cuomo, R., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3550 · Cited by 34
Prise en charge du cancer rénal métastatique
Méjean, A., & Lebrét, T. (2008) · The French Journal of Urology · doi:10.1016/s1166-7087(08)74558-5 · Cited by 33
Chen, B., Lu, Y., Lin, C., Chen, T. W., Wu, P., Hsu, C., Yu, C., Wei, S., Cheng, A., & Shih, T. T. (2016) · BMC Cancer · doi:10.1186/s12885-016-2494-8 · Cited by 31
3-D Longitudinal Imaging of Tumor Angiogenesis in Mice in Vivo Using Ultrafast Doppler Tomography
Demené, C., Payen, T., Dizeux, A., Barrois, G., Gennisson, J., Bridal, S. L., & Tanter, M. (2019) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.12.010 · Cited by 32
Vascular targeting therapy: potential benefit depends on tumor and host related effects.
Horsman, M. R., Bohn, A. B., & Busk, M. (2010) · PubMed · Cited by 34
Nonlinear Modeling and Simulation of Tumor Growth
Cristini, V., Frieboes, H. B., Li, X., Lowengrub, J. S., Macklin, P., Sanga, S., Wise, S. M., & Zheng, X. (2008) · Modeling and simulation in science, engineering & technology · doi:10.1007/978-0-8176-4713-1_6 · Cited by 33
Mathematical modelling of tissue-engineered angiogenesis
Lemon, G., Howard, D. J., Tomlinson, M. J., Buttery, L. D. K., Rose, F. R. A. J., Waters, S. L., & King, J. R. (2009) · Mathematical Biosciences · doi:10.1016/j.mbs.2009.07.003 · Cited by 38
A surrogate marker to monitor angiogenesis at last
Schneider, M., Tjwa, M., & Carmeliet, P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.12.014 · Cited by 31
A Physiologic Imaging Pilot Study of Breast Cancer Treated with AZD2171
Miller, K. D., Miller, M. A., Mehrotra, S., Agarwal, B., Mock, B. H., Zheng, Q., Badve, S., Hutchins, G. D., & Sledge, G. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0219 · Cited by 31
When Does the Presence of the Target Predict Response to the Targeted Agent?
Bergsland, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6913 · Cited by 31
Radiotherapy in combination with vascular-targeted therapies
Ciric, E., & Sersa, G. (2010) · Radiology and Oncology · doi:10.2478/v10019-010-0025-9 · Cited by 30
Dietary Restriction Promotes Vessel Maturation in a Mouse Astrocytoma
Urits, I., Mukherjee, P., Meidenbauer, J. J., & Seyfried, T. N. (2011) · Journal of Oncology · doi:10.1155/2012/264039 · Cited by 30
Stetler‐Stevenson, W. G., & Gavil, N. V. (2014) · Connective Tissue Research · doi:10.3109/03008207.2013.867339 · Cited by 32
Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms
Bellati, F., Napoletano, C., Gasparri, M. L., Ruscito, I., Marchetti, C., Pignata, S., Tomao, F., Panici, P. B., & Nuti, M. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.09.006 · Cited by 31
Pastorino, F., Brignole, C., Loi, M., Paolo, D. D., Fiore, A. D., Perri, P., Pagnan, G., & Ponzoni, M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00190 · Cited by 31
Elias, A., Crayton, S. H., Warden‐Rothman, R., & Tsourkas, A. (2014) · Scientific Reports · doi:10.1038/srep05840 · Cited by 30
Sun, C., Gao, S., Tan, Y., Zhang, Z., & Xu, H. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00254 · Cited by 30
Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
Yuan, J., Li, X., & Yu, S. (2021) · Cancer Control · doi:10.1177/10732748211038424 · Cited by 31
Recent advances in smart nanoplatforms for tumor non-interventional embolization therapy
Dong, H., Yang, D., Hu, Y., & Song, X. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01548-w · Cited by 31
Brackenier, C., Kinget, L., Cappuyns, S., Verslype, C., Beuselinck, B., & Dekervel, J. (2023) · Cancers · doi:10.3390/cancers15020348 · Cited by 30
Mode of action and clinical impact of VEGF signaling inhibitors
Soltau, J., & Drevs, J. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.19 · Cited by 30
Why does androgen deprivation enhance the results of radiation therapy?
Wo, J. Y.-L., & Zietman, A. L. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.008 · Cited by 30
MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response
Matejuk, A., Collet, G., Nadim, M., Grillon, C., & Kieda, C. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-013-0231-4 · Cited by 30
Wuthrick, E. J., Curran, W. J., Camphausen, K. A., Lin, A., Glass, J., Evans, J. J., Andrews, D. W., Axelrod, R. A., Shi, W., Werner‐Wasik, M., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.05.034 · Cited by 30
Minowa, T., Kawano, K., Kuribayashi, H., Shiraishi, K., Sugino, T., Hattori, Y., Yokoyama, M., & Maitani, Y. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605367 · Cited by 30
Abuqayyas, L., & Balthasar, J. P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9357-2 · Cited by 30
Fu, B. M., Yang, J., Cai, B., Fan, J., Zhang, L., & Zeng, M. (2015) · Scientific Reports · doi:10.1038/srep15697 · Cited by 30
Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy
Le, Q., Suh, J., & Oh, Y. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0333-y · Cited by 31
MRI-Based Characterization of Vascular Disruption by 5,6-Dimethylxanthenone-Acetic Acid in Gliomas
Seshadri, M., & Ciesielski, M. J. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.68 · Cited by 30
Liu, F., Tan, G., Li, J., Dong, X., Krissansen, G. W., & Sun, X. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00542.x · Cited by 30
Eichhorn, M., Becker, S., Strieth, S., Werner, A., Sauer, B., Teifel, M., Ruhstorfer, H., Michaelis, U., Griebel, J., Brix, G., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.1.2346 · Cited by 30
Advances in Chemotherapy for Colorectal Cancer
Bernold, D. M., & Sinicrope, F. A. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.04.016 · Cited by 34
Rama, E., May, J., Rix, A., Lammers, T., & Kiessling, F. M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152346 · Cited by 31
Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature
Subudhi, S., Lee, S., & Jain, R. K. (2026) · Cell · doi:10.1016/j.cell.2026.03.016 · Cited by 31
Self-citationSystemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma
Tazi, E. G., Essâdi, I., M’rabti, H., Touyar, A., & Errihani, H. (2011) · North American Journal of Medical Sciences · doi:10.4297/najms.2011.3167 · Cited by 29
Nanomedicine as a potent strategy in melanoma tumor microenvironment
Pautu, V., Leonetti, D., Lepeltier, É., Clere, N., & Passirani, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.014 · Cited by 33
A revisited concept. Tumors: Wounds that do not heal
Ribatti, D., & Tamma, R. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.05.016 · Cited by 30
Load Forecasting using Autoregressive Integrated Moving Average and Artificial Neural Network
Velasco, L. C., Lim-Polestico, D. L., Paolo, G., Bryan, M., & Felicisimo, B. (2018) · International Journal of Advanced Computer Science and Applications · doi:10.14569/ijacsa.2018.090704 · Cited by 29
Lin, L., Du, Y., Hao, J., WU, R. T., & Du, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114322 · Cited by 31
Möckel, D., Bartneck, M., Niemietz, P. M., Wagner, M., Ehling, J., Rama, E., Weiler, M., Gremse, F., Eulberg, D., Pola, R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.044 · Cited by 29
Chen, T. W., Dai, M., Tseng, L., Chen, S., Chao, T., Chao, T., Chang, Y., Chiu, C., Liu, C.-T., Lin, C., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.5456 · Cited by 30
Multi-input Optimal Control Problems for Combined Tumor Anti-angiogenic and Radiotherapy Treatments
Ledzewicz, U., & Schättler, H. (2011) · Journal of Optimization Theory and Applications · doi:10.1007/s10957-011-9954-8 · Cited by 29
Schellerer, V. S., Croner, R. S., Weinländer, K., Hohenberger, W., Stürzl, M., & Naschberger, E. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700671 · Cited by 29
Tumour thermotolerance, a physiological phenomenon involving vessel normalisation
Dings, R. P. M., Loren, M. L., Zhang, Y., Mikkelson, S., Mayo, K. H., Corry, P. M., & Griffin, R. J. (2011) · International Journal of Hyperthermia · doi:10.3109/02656736.2010.510495 · Cited by 31
Leggas, M. L., Kuo, K., Robert, F., Cloud, G., deShazo, M., Zhang, R., Li, M., Wang, H., Davidson, S., & Rinehart, J. J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0767-x · Cited by 33
Snoeren, N., Voest, E. E., Bergman, A. M., Dalesio, O., Verheul, H. M. W., Tollenaar, R. A. �. �., van der Sijp, J. R., Schouten, S. B., Rinkes, I. H. M. B., & van Hillegersberg, R. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-545 · Cited by 34
Incorporating VEGF-targeted therapy in advanced urothelial cancer
Narayanan, S., & Srinivas, S. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016667179 · Cited by 29
Adachi, E., Sakai, K., Nishiuchi, T., Imamura, R., Sato, H., & Matsumoto, K. (2016) · Oncotarget · doi:10.18632/oncotarget.12221 · Cited by 31
Prognostic value of circulating endothelial cells in metastatic colorectal cancer
Rahbari, N. N., Schölch, S., Bork, U., Kahlert, C., Schneider, M. A., Rahbari, M., Büchler, M. W., Weitz, J., & Reißfelder, C. (2017) · Oncotarget · doi:10.18632/oncotarget.16397 · Cited by 29
MECHANISMS OF ANTICANCER DRUGS RESISTANCE: AN OVERVIEW
Chorawala, M. R., Oza, P., & Shah, G. B. (2012) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2012.040101 · Cited by 45
Larsson, C., Groote, I. R., Vardal, J., Kleppestø, M., Odland, A., Brandal, P., Due‐Tønnessen, P., Holme, S. S., Hope, T. R., Meling, T. R., et al. (2020) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2020.01.012 · Cited by 29
Antiangiogenic Effects of Noscapine Enhance Radioresponse for GL261 Tumors
Newcomb, E. W., Lukyanov, Y., Alonso‐Basanta, M., Esencay, M., Smirnova, I., Schnee, T., Shao, Y., Devitt, M. L., Zagzag, D., McBride, W. H., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.04.020 · Cited by 29
Targeted therapy in advanced non-small cell lung cancer (NSCLC): Where do we stand?
Azim, H. A., & Ganti, A. K. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.07.014 · Cited by 29
Molema, G. (2002) · Pharmaceutical Research · doi:10.1023/a:1020312220968 · Cited by 32
Systemic targeted radionuclide therapy: Potential new areas
Wong, J. Y. C. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.05.029 · Cited by 31
Rahman, M. A., & Ali, M. M. (2024) · Cancers · doi:10.3390/cancers16172975 · Cited by 28
Safety of Bevacizumab in Patients with Metastatic Breast Cancer
Hamilton, E. P., & Blackwell, K. (2011) · Oncology · doi:10.1159/000328757 · Cited by 29
Estimation of tumor microvessel density by MRI using a blood pool contrast agent
Krishna, K. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000392 · Cited by 28
Beppu, T., Terasaki, K., Sasaki, T., Sato, Y., Tomabechi, M., Kato, K., Sasaki, M., & Ogasawara, K. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001377 · Cited by 28
Pan, J., Zhu, S., Huang, J., Liang, J., Zhang, D., Zhao, X., Ding, H., Li, Q., Shi, C., Luo, L., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00524 · Cited by 28
Endothelial Progenitors in the Tumor Microenvironment
Testa, U., Pelosi, E., & Castelli, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-44518-8_7 · Cited by 29
Al-Suede, F. S. R., Farsi, E., Ahamed, M. B. K., Ismail, Z., Majid, A. S. A., & Majid, A. M. S. A. (2014) · Journal Of Biochemical Technology · Cited by 28
Physiological Mechanisms of Treatment Resistance
Vaupel, P. W. (2009) · Medical radiology · doi:10.1007/978-3-540-74386-6_15 · Cited by 30
Zhu, X., Zhang, J., Fan, P.-L., Xiong, Y., Zhuang, P., Zhang, W., Xu, H.-X., Gao, D., Kong, L., Wang, L., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-28 · Cited by 28
Ohta, M., Kawabata, T., Yamamoto, M., Tanaka, T., Kikuchi, H., Hiramatsu, Y., Kamiya, K., Baba, M., & Konno, H. (2009) · Surgery Today · doi:10.1007/s00595-009-4020-y · Cited by 28
Schmidt, B. H., Lee, H., Ryeom, S. W., & Yoon, S. S. (2012) · Current Angiogenesis · doi:10.2174/2211552811201030169 · Cited by 29
Bullitt, E., Ewend, M. G., Vredenburgh, J. J., Friedman, A. H., Lin, W., Wilber, K. P., Zeng, D., Aylward, S., & Reardon, D. A. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.067 · Cited by 28
Pseudoprogression and Treatment Effect
Jahangiri, A., & Aghi, M. K. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.01.002 · Cited by 28
Shi, S., Chen, L., & Huang, G. (2013) · Medical Oncology · doi:10.1007/s12032-013-0698-1 · Cited by 31
Progress in Cancer Chemotherapy with Special Stress on Molecular-targeted Therapy
Saijo, N. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq035 · Cited by 32
Deng, G., Zhao, D.-L., Li, G., Yu, H., & Teng, G. (2011) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-011-0179-x · Cited by 28
Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors
Askoxylakis, V., Arvanitis, C., Wong, C. S. F., Ferraro, G. B., & Jain, R. K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.011 · Cited by 28
Self-citationPhotobiomodulation of breast and cervical cancer stem cells using low-intensity laser irradiation
Kiro, N., Hamblin, M. R., & Abrahamse, H. (2017) · Tumor Biology · doi:10.1177/1010428317706913 · Cited by 30
Restriction of drug transport by the tumor environment
Nandigama, R., Upcin, B., Aktas, B. H., Ergün, S., & Henke, E. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1744-z · Cited by 31
Fan, Q., Tao, Z., Yang, H., Shi, Q., Wang, H., Jia, D., Wan, L., Zhang, J., Cheng, J., & Lu, X. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.018 · Cited by 29
VEGF and angiogenesis: implications for breast cancer therapy
Drevs, J. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)70287-8 · Cited by 28
Kim, Y. R., Yudina, A., Figueiredo, J.-L., Reichardt, W., Hu‐Lowe, D. D., Petrovsky, A., Kang, H. W., Torres, D. M., Mahmood, U., Weissleder, R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-2619 · Cited by 28
Teng, L., Jin, K., He, K., Wang, H., Cao, J., & Yu, D.-C. (2010) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(10)70062-9 · Cited by 31
Metronomic Dosing of Chemotherapy: Applications in Pediatric Oncology
Stempak, D., Seely, D., & Baruchel, S. (2006) · Cancer Investigation · doi:10.1080/07357900600705599 · Cited by 29
Bu, X., Khankaldyyan, V., Gonzales-Gomez, I., Groshen, S. G., Ye, W., Zhuo, S., Pons, J., Stratton, J., Rosenberg, S., & Laug, W. E. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700089 · Cited by 28
Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition
Bozec, A., Gros, F., Penault-Llorca, F. M., Formento, P., Cayre, A., Dental, C., Étienne-Grimaldi, M.-C., Fischel, J., & Milano, G. A. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.013 · Cited by 32
Bevacizumab for Advanced Breast Cancer
Traina, T. A., Rugo, H. S., & Dickler, M. N. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.03.006 · Cited by 28
Bevacizumab in the treatment of colorectal cancer
Cilley, J., Barfi, K., Benson, A. B., & Mulcahy, M. F. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.5.739 · Cited by 31
Ciccolini, J., Benzekry, S., Lacarelle, B., Barbolosi, D., & Barlési, F. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506689112 · Cited by 28
Mao, D., Wang, H., Guo, H., Che, X., Chen, M. H., Li, X., Li, X., Huo, J., & Chen, Y. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155191 · Cited by 27
Chen, H., Modiano, M., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., Leighl, N. B., Riess, J. W., Kuo, C. J., Liu, L., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.735 · Cited by 27
Introduction to polymeric drug delivery systems
Harrison, K. (2007) · Elsevier eBooks · doi:10.1533/9781845693640.33 · Cited by 30
Interstitial Flow in Cancerous Tissue: Effect of Considering Remodeled Capillary Network
Sefidgar, M., & Soltani, M. (2014) · Journal of Tissue Science & Engineering · doi:10.4172/2157-7552.s4-003 · Cited by 27
Gao, H., Xue, J., Zhou, L., Lan, J., He, J., Na, F., Yang, L., Deng, L., & Lü, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.011 · Cited by 27
Lord, R., Suddle, A. R., & Ross, P. J. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02545.x · Cited by 27
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Medicine
- Published
- 2001-09
- Volume
- 7
- Issue
- 9
- Pages
- 987-989
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1603230122
- Cited by
- 2,184
- References
- 26
- Citations by year
- 2026: 58 · 2025: 65 · 2024: 61 · 2023: 88 · 2022: 97 · 2021: 91 · 2020: 93 · 2019: 91 · 2018: 69 · 2017: 94 · 2016: 82 · 2015: 106 · 2014: 94 · 2013: 101 · 2012: 124
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, tumor vasculature normalization, solid tumors, cancer prevention, combination therapy, drug delivery to tumors, tumor vasculature
- MeSH terms
- Blood Vessels, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.